Free press releases distribution network?

Agency / Source: Creative Biolabs

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Creative Biolabs Announces Bi-specific Antibody Production - In order to increase the efficacy of current therapeutic antibodies, Creative Biolavs, an industry leader in the field of antibody engineering field, has developed CeativeAbTM antibodies - Creative-Biolabs.com
Creative Biolabs Announces Bi-specific Antibody Production

 

PRZOOM - /newswire/ - Shirley, NY, United States, 2015/09/10 - In order to increase the efficacy of current therapeutic antibodies, Creative Biolavs, an industry leader in the field of antibody engineering field, has developed CeativeAbTM antibodies - Creative-Biolabs.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bi-specific antibodies (BsAbs) are bioengineered antibodies that contain two different binding sites within a single molecule, which can specifically bind two different types of antigens. The most widely used application of bi-specific antibody is in cancer immunotherapy, which creates a therapeutic treatment approach for diseases with specific medical needs.

Compared with traditional antibodies, bi-specific antibodies have many advantages. The two arms can bring an antigen-expressing cell in close proximity to a killing cell, thus destroy the tumor cell. By binding to two different epitopes on an antigen, these two binding sites can significantly increase affinity or internalization rates of particular antigens on a cell's surface. They usually have a higher cytotoxic potential to bind to antigens with low expression level. Binding tumor cells utilizing a bi-specific antibody-drug conjugate (ADC) also holds great promise for the future development of therapeutics in various diseases.

With the development of antibody engineering, many types of bi-specific antibodies have been designed to enable short half-life, immunogenicity and side-effects caused by cytokine liberation. They include tri-functional antibodies, chemically linked Fabs and various types of bivalent and trivalent single-chain variable fragments (scFvs) and fusion proteins mimicking the variable domains of two antibodies. The furthest developed of these newer formats are the bi-specific T-cell engagers (BiTEs) and mAb2's, antibodies engineered to contain an Fcab antigen-binding fragment instead of the Fc constant region.

Creative Biolabs offers various types of bi-specific antibodies, including tri-functional antibodies and chemically linked Fabs, bivalent and bi-specific scFvs (tandem scFv, diabodies), bi-specific T-cell engagers (BiTEs) and scFv-Fab fusion proteins.

Based on various antibody formats such as IgGs, Fabs and scFvs, our Creative Discovery Platform™ provides a series of bi-specific antibodies to satisfy various customers' needs. We provide construction (expression & purification) as well as recombinant antibody production at scales£ ranging from hundreds of micrograms to grams level.

About Creative Biolabs

Creative Biolabs (creative-biolabs.com) is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and drug development. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of satisfied clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world. learn more about Creative Biolabs.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Creative Biolabs

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Creative Biolabs Announces Bi-specific Antibody Production

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Candy Swift - Creative-Biolabs.com 
631-871-5806 contact[.]creative-biolabs.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Creative Biolabs securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Creative Biolabs / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Al Rowaad Advocates & Legal Consultants

Visit  NAKIVO, Inc.

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today